• Pitch Reviews
  • Posts
  • The Next Generation Of Psychedelic Medicine Is Botanical

The Next Generation Of Psychedelic Medicine Is Botanical

The Rules:

Every week I breakdown startup pitches with the added hook that you can invest whether you’re accredited or not (if you don't know what that means, click here).

I base my review on a 3-minute founder pitch and some light diligence.

My scoring system is not a validation of idea, or grading for likelihood of success. It just means, all things being equal at launch — this startup has these boxes checked.

What I look for:

  1. Founder — ability to lead, sell into and influence a given market

  2. Idea — is it inevitable or solving a BIG problem in a scaleable way

  3. TAM — how big is the total addressable market

  4. Traction — do they have meaningful early traction

  5. Unfair Advantage — do they have a competitive edge


Company Overview

Ei Ventures is a leading plant and life sciences company focused on botanical psychedelic therapies 👉 Check the Charts 📈 

Key People: David Nikzad (opened the first medical marijuana dispensary in California)

Traction: Ei Ventures has control IP for three botanical psychedelic formulations- Psilly, MY-D, and MY-MDMA; with plans to launch its mental wellness and health app partnerships and MANA medicinal mushroom nutraceuticals in early 2022.

Terms & Takeaway

Invest in Ei Ventures here 👉 Term Sheet

Security Type: Reg A+
Pre-Money Valuation: $$269,400,000
Raised (as of publishing): $20,435,292
Minimum Investment: $498.94

Here's what I like: Nearly a billion people worldwide struggle with mental illness. Of these, 284 million suffer from an anxiety disorder. In fact, the global economic costs of this mental health crisis will reach over $15 trillion by 2030 (including more than 12 billion working days lost). The opportunity here is obvious and that’s why we seem to be entering something of a mental health gold rush — particularly in the psychedelic space. Ei Ventures has a founding crew that has been actively pioneering in the medical marijuana field for literally decades and if the three botanical psychedelic formulations prove to treat those suffering from PTSD and other anxiety-based conditions without the terrible side effects, as early trials have so far suggested, then Ei Ventures is in business!

Here's what I don't love: I’m not going to sugar coat this folks… the price is UTTERLY ridiculous. That said, it has not deterred investors from putting in more than $20M at this share price 🤷‍♂️ I love the mission, the founders and believe there is something to this having witnessed first hand successful treatment using psychedelics.

Who should invest and why: If you’re a value investor, you’ve probably already clicked off. I always like being able to purchase actual stock and $500 minimum isn’t too steep of an ask, despite the crazy small allocation. For me, I tend to ignore the early valuations of companies with strong fundamentals, IP and enormous TAM, especially when not investing a large sum of money (though this is pushing it😆). In the case of Ei Ventures, I think if you or someone close to you suffers from anxiety this opportunity may speak to you.

As always, startup investing is super high-risk, anything can happen.

Invest in Ei Ventures here 👉 Term Sheet

Questions, DM me 🤳 @kitun.

Disclaimer: It goes without saying, but this information should not be constituted as financial advice, my investing opinions are my own and all diligence is the responsibility of each individual investor.